Interleukin‑6 and ischemic stroke: From mechanisms to clinical prospects (Review)

neuroinflammation is a central component of the pathophysiology of ischemic stroke (iS).Suppressing excessive inflammatory responses after stroke can markedly improve patient outcomes.interleukin-6 (il-6), a key mediator of the inflammatory cascade, serves a notable role in the pathological process of acute iS through multiple mechanisms.elevated serum il-6 levels serve as an important biomarker for predicting the onset and recurrence of iS and are closely associated with disease severity and prognosis.Anti-inflammatory interventions are notably important during the acute phase and secondary prevention of stroke.currently, therapeutic strategies targeting the il-6/il-6r signaling axis are under investigation and have shown promising clinical potential.The present review summarizes the important role of il-6 in neuroinflammation associated with iS, its association with disease severity and prognosis and previous advances in anti-inflammatory therapeutic strategies targeting the il-6/il-6r pathway during both the acute phase and secondary prevention of iS.Contents 1. introduction 2. Pathological mechanism of acute iS (aiS) 3. il-6 4. il-6 participates in the pathological mechanism of aiS 5. role of il-6 in iS 6. Therapeutic studies targeting the il-6/il-6r axis 7. conclusions and future perspectives Interleukin-6 and ischemic stroke: From mechanisms to clinical prospects (Review)